title: Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity.
abstract: Recent studies have suggested that elevated plasma C-reactive protein (CRP) levels are associated with the features of insulin resistance syndrome. In the present study, we have examined the contribution of body composition measured by hydrostatic weighing and of abdominal adipose tissue (AT) accumulation assessed by computed tomography to the variation in plasma CRP levels associated with atherogenic dyslipidemia of the insulin resistance syndrome in a sample of 159 men, aged 22 to 63 years, covering a wide range of adiposity (body mass index values from 21 to 41 kg/m(2)). Plasma CRP levels showed positive and significant correlations with body fat mass (r=0.41, P<0.0001), waist girth (r=0.37, P<0.0001), and visceral AT accumulation measured by computed tomography at L4 to L5 (r=0.28, P<0.0003). Although CRP levels were associated with plasma insulin levels measured in the fasting state and after a 75-g oral glucose load, no significant correlations were found with plasma lipoprotein levels. Finally, comparison of body fatness, of abdominal fat accumulation, and of the features of the insulin resistance syndrome across quintiles of CRP revealed major differences in body fatness and in indices of abdominal AT accumulation between the lowest and the highest CRP quintiles, whereas no significant differences were found for variables of the plasma lipoprotein-lipid profile. These results suggest that obesity and abdominal AT accumulation are the critical correlates of elevated plasma CRP levels found in men with atherogenic dyslipidemia of the insulin resistance syndrome.
authors.affiliation: Québec Heart Institute, Laval Hospital Research Center, Sainte-Foy, Québec, Canada.
authors.forename: I
authors.initials: I
authors.lastname: Lemieux
authors.forename: A
authors.initials: A
authors.lastname: Pascot
authors.forename: D
authors.initials: D
authors.lastname: Prud'homme
authors.forename: N
authors.initials: N
authors.lastname: Alméras
authors.forename: P
authors.initials: P
authors.lastname: Bogaty
authors.forename: A
authors.initials: A
authors.lastname: Nadeau
authors.forename: J
authors.initials: J
authors.lastname: Bergeron
authors.forename: J P
authors.initials: JP
authors.lastname: Després
mesh_terms: D000005:Abdomen / Q000254:growth & development; D000273:Adipose Tissue / Q000254:growth & development; D000328:Adult; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology*; D001823:Body Composition; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000209:etiology*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D012307:Risk Factors; D013577:Syndrome; D013927:Thrombosis / Q000097:blood; D014781:Viscera / Q000254:growth & development
chemical_list: D007328:Insulin; D008074:Lipoproteins; D002097:C-Reactive Protein